{"disease":{"id":"vascular-disease","name":"vascular disease"},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"ticagrelor","indication_name":"Peripheral vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brilinta","generic_name":"ticagrelor","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor [EPC]","quality_score":10,"revenue":"1100","mechanism":null},{"drug_id":"atorvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"inclisiran","indication_name":"Atherosclerotic cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqvio","generic_name":"INCLISIRAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":59,"revenue":"863","mechanism":"Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors."},{"drug_id":"prasugrel","indication_name":"Prevention of recurrence of ischemic cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effient","generic_name":"PRASUGREL","company_name":"Cosette","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor","quality_score":80,"revenue":"400","mechanism":"Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Reduction of thrombotic cardiovascular events in patients with atherosclerotic disease, including those with a recent ischemic stroke or peripheral artery disease (PAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"colchicine","indication_name":"Cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colcrys","generic_name":"COLCHICINE","company_name":"Scilex Pharms","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Alkaloid [EPC]","quality_score":10,"revenue":null,"mechanism":"Colcrys works by inhibiting the activity of a specific enzyme called serine/threonine-protein kinase pim-1."},{"drug_id":"simvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"brilinta","indication_name":"Peripheral vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brilinta","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naftidrofuryl","indication_name":"Cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nafronyl","generic_name":"naftidrofuryl","company_name":"","drug_phase":"unknown","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"naftidrofuryl","quality_score":null,"revenue":null,"mechanism":"Nafronyl works by interacting with the 5-hydroxytryptamine receptor 2A to improve blood flow and reduce vascular resistance."},{"drug_id":"rosuvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"tolazoline","indication_name":"Cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasodil","generic_name":"TOLAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"tolazoline","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sotagliflozin","indication_name":"Chronic kidney disease at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"sotagliflozin","indication_name":"Diabetes mellitus type 2 at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"lovastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"azapetine","indication_name":"Peripheral vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ilidar","generic_name":"azapetine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"azapetine","quality_score":null,"revenue":null,"mechanism":"Ilidar works by inhibiting platelet aggregation, which helps to improve blood flow and reduce the risk of blood clots."},{"drug_id":"naftidrofuryl-oxalate","indication_name":"Cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praxilene","generic_name":"naftidrofuryl oxalate","company_name":"Merck Serono (originally Lipha)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"5-HT2 receptor antagonist, Peripheral vasodilator","quality_score":31,"revenue":null,"mechanism":"A 5-HT2 receptor antagonist that improves peripheral blood flow and cellular metabolism by blocking serotonin-mediated vasoconstriction and enhancing aerobic metabolism in ischaemic tissues."},{"drug_id":"ethaverine","indication_name":"Peripheral vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Barbonin","generic_name":"ETHAVERINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"ethaverine","quality_score":22,"revenue":null,"mechanism":"Barbonin works by improving blood flow to the affected areas of the body."},{"drug_id":"bifemelane","indication_name":"Cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"4-(O-Benzylphenoxy)-N-Methylbutylamine","generic_name":"BIFEMELANE","company_name":"","drug_phase":"phase_2","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"bifemelane","quality_score":36,"revenue":null,"mechanism":"BIFEMELANE works by inhibiting the enzyme Amine oxidase [flavin-containing] A, which plays a role in the breakdown of certain neurotransmitters."},{"drug_id":"fluvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"bencyclane","indication_name":"Cerebrovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzcyclan","generic_name":"BENCYCLANE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"bencyclane","quality_score":null,"revenue":null,"mechanism":"Bencyclane works by relaxing blood vessels and improving blood flow to the brain."}],"pipeline":[],"offLabel":[],"totalMarketed":24,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03243253","title":"The Association of Fast Food Densities With Mortality From Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":17000000,"lead_sponsor_name":"Chinese Academy of Sciences","has_results":false},{"nct_id":"NCT03259100","title":"Temperature and Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":17000000,"lead_sponsor_name":"Chinese Academy of Sciences","has_results":false},{"nct_id":"NCT05853536","title":"In Silico Trials of Surgical Interventions","phase":"","overall_status":"UNKNOWN","enrollment_count":13977257,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT06406998","title":"Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD","phase":"","overall_status":"RECRUITING","enrollment_count":5461222,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03534908","title":"Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study","phase":"","overall_status":"UNKNOWN","enrollment_count":5000000,"lead_sponsor_name":"Wuhan University","has_results":false},{"nct_id":"NCT05221528","title":"Association Between Lipid Profiles and Cardiovascular Events","phase":"","overall_status":"UNKNOWN","enrollment_count":4234339,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06571747","title":"Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3668428,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT06517134","title":"Prescribing Patterns of Antihypertensive Drugs in Uncomplicated Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":3325032,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05466825","title":"The Global Cardiovascular Risk Consortium","phase":"","overall_status":"RECRUITING","enrollment_count":3000000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT05837364","title":"Predicting Risk of Atrial Fibrillation and Association With Other Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2159663,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT03904732","title":"Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU","phase":"","overall_status":"COMPLETED","enrollment_count":2000000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07357116","title":"Alteration of the Risk of CArdiovascular DIseases After Pneumonia","phase":"","overall_status":"COMPLETED","enrollment_count":2000000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04506528","title":"COVID EHR COHORT at the University of Wisconsin","phase":"","overall_status":"COMPLETED","enrollment_count":1634381,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT04091035","title":"Prevalence and Risk Factors for Common Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Anna Nordström","has_results":false},{"nct_id":"NCT07205978","title":"Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT07196917","title":"Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05021575","title":"Effects of COVID-19 Pandemic on a Health Care System: Case Study of the CirculatORy System in LiThuania","phase":"","overall_status":"COMPLETED","enrollment_count":839678,"lead_sponsor_name":"Vilnius University","has_results":false},{"nct_id":"NCT06409481","title":"Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":800000,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT07393412","title":"Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":800000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05220917","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":781430,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03492580","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":714582,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04834843","title":"Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":700000,"lead_sponsor_name":"Wonju Severance Christian Hospital","has_results":false},{"nct_id":"NCT02931500","title":"Machine Learning for Identification of Future Disease Development: A Nationwide Cohort Study (MILESTONE)","phase":"","overall_status":"UNKNOWN","enrollment_count":510000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04067297","title":"Using Big Data to Conduct Innovative Cardiovascular Clinical Trials","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500000,"lead_sponsor_name":"Institute for Clinical Evaluative Sciences","has_results":false},{"nct_id":"NCT04294771","title":"JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors","phase":"","overall_status":"UNKNOWN","enrollment_count":500000,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT07465926","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","phase":"","overall_status":"COMPLETED","enrollment_count":451036,"lead_sponsor_name":"Chung Shan Medical University","has_results":false},{"nct_id":"NCT02635685","title":"Clinical Decision Support for Stroke Prevention in Atrial Fibrillation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":442105,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT06859502","title":"National Database of the Virtual Institute of Cerebrovascular Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":312800,"lead_sponsor_name":"Fondazione Don Carlo Gnocchi Onlus","has_results":false},{"nct_id":"NCT04903041","title":"A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).","phase":"","overall_status":"SUSPENDED","enrollment_count":300000,"lead_sponsor_name":"Jaime Marino","has_results":false},{"nct_id":"NCT04775836","title":"An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":300000,"lead_sponsor_name":"Ministry of Science and Technology of the People´s Republic of China","has_results":false},{"nct_id":"NCT05925699","title":"National Database of the Virtual Institute of Cerebrovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":285600,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07141914","title":"A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World","phase":"","overall_status":"COMPLETED","enrollment_count":285327,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05248412","title":"The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06978348","title":"Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology.","phase":"","overall_status":"RECRUITING","enrollment_count":244296,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05073692","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","phase":"","overall_status":"COMPLETED","enrollment_count":241981,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT04110288","title":"VQI DELTA Paclitaxel Device Safety Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":219483,"lead_sponsor_name":"Lahey Clinic","has_results":false},{"nct_id":"NCT04047147","title":"Evaluation of the Million Hearts CVD Risk Reduction Model","phase":"","overall_status":"UNKNOWN","enrollment_count":210000,"lead_sponsor_name":"Mathematica Policy Research, Inc.","has_results":false},{"nct_id":"NCT05974345","title":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":204691,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06223906","title":"A Registry Study of Biomarkers in Heart Valve Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases","has_results":false},{"nct_id":"NCT03958760","title":"Characteristics, Treatment, and Economic Burden of Patients With CVD,CKD or at High Cardiovascular Risk","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT03225586","title":"Prospective Urban Rural Epidemiology Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT02681848","title":"What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?","phase":"","overall_status":"UNKNOWN","enrollment_count":180000,"lead_sponsor_name":"University of Bristol","has_results":false},{"nct_id":"NCT03413176","title":"Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.","phase":"","overall_status":"COMPLETED","enrollment_count":150000,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT04541498","title":"Impact of Air Pollution and Climate Changes on the Epidemiology of Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":150000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT03299010","title":"10-year Risk Prediction Models of Complications and Mortality of DM in Hong Kong","phase":"","overall_status":"COMPLETED","enrollment_count":141516,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04302974","title":"Cohort Study on Patient Outcomes, Effectiveness and Cost-effectiveness of Intervention Programmes for DM/HT Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04281823","title":"DeBakey Cardiovascular Magnetic Resonance Study","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Dipan Shah","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}